Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 10/20 | 0.73 |
| ▸ | PIK3CG | P48736 | 4/20 | 0.67 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.67 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.67 |
| ▸ | SRC | P12931 | 9/20 | 0.52 |
| ▸ | ABL1 | P00519 | 4/20 | 0.52 |
| ▸ | PIK3CB | P42338 | 3/20 | 0.49 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.49 |
| ▸ | PRKDC | P78527 | 1/20 | 0.49 |
| ▸ | BTK | Q06187 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29651732 | 1.00 | PIK3CD (0.73) | PIK3CDPIK3CGPIK3R1CSNK1ESRC | |
| SCHEMBL11219 | 0.93 | PIK3CD (0.75) | PIK3CDPIK3CGPIK3R1CSNK1ESRC | |
| SCHEMBL29651733 | 0.93 | PIK3CD (0.75) | PIK3CDPIK3CGPIK3R1CSNK1ESRC | |
| SCHEMBL29651695 | 0.92 | PIK3CD (0.76) | PIK3CDPIK3CGPIK3R1CSNK1ESRC | |
| SCHEMBL10357 | 0.92 | PIK3CD (0.76) | PIK3CDPIK3CGPIK3R1CSNK1ESRC | |
| SCHEMBL10506 | 0.92 | PIK3CD (0.77) | PIK3CDPIK3CGPIK3R1CSNK1ESRC | |
| SCHEMBL29651743 | 0.92 | PIK3CD (0.77) | PIK3CDPIK3CGPIK3R1CSNK1ESRC | |
| SCHEMBL11297 | 0.91 | PIK3CD (0.83) | PIK3CDPIK3CGPIK3R1CSNK1ESRC | |
| SCHEMBL29651622 | 0.91 | PIK3CD (0.83) | PIK3CDPIK3CGPIK3R1CSNK1ESRC | |
| SCHEMBL11399 | 0.90 | PIK3CD (0.75) | PIK3CDPIK3CGPIK3R1CSNK1ESRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11858907-B2 | Kinase modulators | RHIZEN PHARMACEUTICALS AG (CH) | 2024-01-02 | — | — | US | claimed |
| EP-4292596-A1 | METHOD AND COMBINATION FOR TREATING TUMORS | Curon Biopharmaceutical (Shanghai) Co., Limited (CN) | 2023-12-20 | — | — | EP | claimed |
| CN-117222413-A | Methods and combinations for treating tumors | 同润生物医药(上海)有限公司 | 2023-12-12 | — | — | CN | claimed |
| US-20200239427-A1 | NOVEL KINASE MODULATORS | RHIZEN PHARMACEUTICALS AG (CH) | 2020-07-30 | — | — | US | claimed |
| EP-2496567-B1 | NOVEL BENZOPYRAN KINASE MODULATORS | RHIZEN PHARMACEUTICALS S A (CH) | 2017-07-12 | — | — | EP | claimed |
| US-20110118257-A1 | NOVEL KINASE MODULATORS | RHIZEN PHARMACEUTICALS SA (CH) | 2011-05-19 | — | — | US | claimed |
| US-20240139198-A1 | METHOD AND COMBINATION FOR TREATING TUMORS | CURON BIOPHARMACEUTICAL (SHANGHAI) CO., LIMITED (CN) | 2024-05-02 | — | — | US | disclosed |
| US-11858907-B2 | Kinase modulators | RHIZEN PHARMACEUTICALS AG (CH) | 2024-01-02 | — | — | US | disclosed |
| US-11858907-B2 | Kinase modulators | RHIZEN PHARMACEUTICALS AG (CH) | 2024-01-02 | — | — | US | disclosed |
| US-11858907-B2 | Kinase modulators | RHIZEN PHARMACEUTICALS AG (CH) | 2024-01-02 | — | — | US | disclosed |
| CN-117222413-A | Methods and combinations for treating tumors | 同润生物医药(上海)有限公司 | 2023-12-12 | — | — | CN | disclosed |
| EP-2916868-B1 | PHARMACEUTICAL COMPOSITIONS CONTAINING A PDE4 INHIBITOR AND A PI3 DELTA OR DUAL PI3 DELTA-GAMMA KINASE INHIBITOR | RHIZEN PHARMACEUTICALS S A (CH) | 2022-05-11 | — | — | EP | disclosed |
| US-11065236-B2 | Pharmaceutical compositions containing a PDE4 inhibitor and a PI3 delta or dual PI3 delta-gamma kinase inhibitor | RHIZEN PHARMACEUTICALS SA (CH) | 2021-07-20 | — | — | US | disclosed |
| US-8642607-B2 | 4H-chromen-4-one compounds as modulators of protein kinases | RHIZEN PHARMACEUTICALS SA (CH) | 2014-02-04 | — | — | US | disclosed |
| US-20120059001-A1 | NOVEL KINASE MODULATORS | INCOZEN THERAPEUTICS PVT. LTD. (IN) | 2012-03-08 | — | — | US | disclosed |
| US-20120059001-A1 | NOVEL KINASE MODULATORS | INCOZEN THERAPEUTICS PVT. LTD. (IN) | 2012-03-08 | — | — | US | disclosed |
| US-20120059001-A1 | NOVEL KINASE MODULATORS | INCOZEN THERAPEUTICS PVT. LTD. (IN) | 2012-03-08 | — | — | US | disclosed |
| US-20110118257-A1 | NOVEL KINASE MODULATORS | RHIZEN PHARMACEUTICALS SA (CH) | 2011-05-19 | — | — | US | disclosed |
| US-20110118257-A1 | NOVEL KINASE MODULATORS | RHIZEN PHARMACEUTICALS SA (CH) | 2011-05-19 | — | — | US | disclosed |
| US-20110118257-A1 | NOVEL KINASE MODULATORS | RHIZEN PHARMACEUTICALS SA (CH) | 2011-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118257-A1 | NOVEL KINASE MODULATORS | PRKCA, PRKCH, PRKCB | PIK3CD 70/4885PIK3CG 99/4885PIK3R1 95/4885 |
| US-20200239427-A1 | NOVEL KINASE MODULATORS | PRKCA, PRKCH, PRKCB | PIK3CD 70/4885PIK3CG 99/4885PIK3R1 95/4885 |
| US-11858907-B2 | Kinase modulators | RPS6KA1, RPS6KA2, PRKAR2A | PIK3CD 103/4885PIK3CG 126/4885PIK3R1 53/4885 |
| US-11065236-B2 | Pharmaceutical compositions containing a PDE4 inhibitor and a PI3 delta or dual PI3 delta-gamma kinase inhibitor | PIK3CD, PIK3R4, PIK3CG | PIK3CD 1/4885PIK3CG 3/4885PIK3R1 21/4885 |
| US-20240139198-A1 | METHOD AND COMBINATION FOR TREATING TUMORS | PDCD1, PDCD1LG2, CD274 | PIK3CD 116/4885PIK3CG 221/4885PIK3R1 45/4885 |
| US-20120059001-A1 | NOVEL KINASE MODULATORS | PRKCA, PRKCH, PRKCB | PIK3CD 70/4885PIK3CG 99/4885PIK3R1 95/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.